[ Back to EurekAlert! ]

Contact: Mary Beth O'Leary
moleary@cell.com
617-397-2802
Cell Press

Framework Mutations are Critical for Broadly Neutralizing HIV-1 Abs

Caption: An effective vaccine against HIV-1 remains elusive, but one promising strategy focuses on designer antibodies that have much broader potency than most normal, exquisitely specific antibodies. These broadly neutralizing antibodies (bNAbs) can handle the high mutation rate of HIV virus particles that makes normal, very specific antibodies useless within a short space of time. A study published by Cell Press on March 28th in the journal Cell reveals surprising mutations in these antibodies that are crucial for strong protection against HIV-1. The findings could guide efforts to design better HIV-1 vaccines.

Credit: Cell, Nussenzweig et al.

Usage Restrictions: Proper Credit Required

Related news release: HIV antibodies that are worth the wait


[ Back to EurekAlert! ]